How I treat smoldering multiple myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Background:

• Smoldering myeloma is a precursor to active multiple myeloma, characterized by specific M-protein levels or bone marrow plasma cell percentages.
• Current management involves observation or clinical trial participation, lacking molecular markers for risk stratification.
• Recent updates to active multiple myeloma definitions may influence treatment timing for smoldering myeloma patients.

Observation:

• Smoldering myeloma presents a clinical heterogeneity, with some patients exhibiting indolent disease and others progressing rapidly to 'early myeloma'.
• Existing diagnostic criteria do not adequately differentiate between low and high-risk smoldering myeloma.
• The bone marrow microenvironment and tumor clone biology are key areas of investigation for understanding disease progression.

Findings:

• No established molecular factors currently exist to predict smoldering myeloma progression risk.
• Emerging data suggests a potential shift towards earlier therapeutic interventions.
• Understanding the biological alterations in tumor cells and the bone marrow niche is essential.

Implications:

• Future recommendations for smoldering myeloma therapy are likely to evolve, emphasizing personalized treatment approaches.
• Identifying predictive biomarkers will be critical for optimizing patient management and clinical trial design.
• This review synthesizes current knowledge, risk factors, biological insights, and clinical trial data for smoldering myeloma.